ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
WuXi Biologics is launching a $1.4 billion project to build a biologic drug R&D and production center in Singapore. The project will add 120,000 L of capacity to the company’s biomanufacturing network by 2026 and is expected to create 1,500 jobs. Meanwhile, Samsung Biologics will pay $350 million for land in Incheon, South Korea, on which it plans to build a second biologic drug production campus. The site is 30% larger than the firm’s current campus in Songdo, South Korea, where it operates three plants and is building a fourth. Samsung expects the project to generate 4,000 jobs by 2032.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter